作者
Luciana P Tavares, Cristiana C Garcia, Marina G Machado, Celso M Queiroz-Junior, Adeline Barthelemy, François Trottein, Marilda M Siqueira, Laura Brandolini, Marcello Allegretti, Alexandre M Machado, LirlaNdia P De Sousa, Mauro M Teixeira
发表日期
2017/12/13
期刊
Frontiers in immunology
卷号
8
页码范围
1799
出版商
Frontiers Media SA
简介
Rationale
Influenza A infections are a leading cause of morbidity and mortality worldwide especially when associated with secondary pneumococcal infections. Inflammation is important to control pathogen proliferation but may also cause tissue injury and death. CXCR1/2 are chemokine receptors relevant for the recruitment of neutrophils. We investigated the role of CXCR1/2 during influenza, pneumococcal, and post-influenza pneumococcal infections.
Methods
Mice were infected with influenza A virus (IAV) or Streptococcus pneumoniae and then treated daily with the CXCR1/2 antagonist DF2162. To study secondary pneumococcal infection, mice were infected with a sublethal inoculum of IAV then infected with S. pneumoniae 14 days later. DF2162 was given in a therapeutic schedule from days 3 to 6 after influenza infection. Lethality, weight loss, inflammation, virus/bacteria counts, and lung injury were assessed.
Results
CXCL1 and CXCL2 were produced at high levels during IAV infection. DF2162 treatment decreased morbidity and this was associated with decreased infiltration of neutrophils in the lungs and reduced pulmonary damage and viral titers. During S. pneumoniae infection, DF2162 treatment decreased neutrophil recruitment, pulmonary damage, and lethality rates, without affecting bacteria burden. Therapeutic treatment with DF2162 during sublethal IAV infection reduced the morbidity associated with virus infection and also decreased the magnitude of inflammation, lung damage, and number of bacteria in the blood of mice subsequently infected with S. pneumoniae.
Conclusion
Modulation of the inflammatory response …
引用总数
201820192020202120222023202431010915112
学术搜索中的文章